Journal Article

Rates of antifungal resistance among Spanish clinical isolates of <i>Cryptococcus neoformans</i> var. <i>neoformans</i>

Alexander Perkins, Alicia Gomez-Lopez, Emilia Mellado, Juan L. Rodriguez-Tudela and Manuel Cuenca-Estrella

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 6, pages 1144-1147
Published in print December 2005 | ISSN: 0305-7453
Published online November 2005 | e-ISSN: 1460-2091 | DOI:
Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans

Show Summary Details


Objectives: Activities in vitro of six antifungal agents were tested against a collection of 317 Cryptococcus neoformans var. neoformans clinical isolates.

Methods: The procedure described in document 7.1 by the European Committee on Antibiotic Susceptibility Testing with minor modifications was employed.

Results: Amphotericin B, itraconazole, voriconazole and ravuconazole exhibited a potent activity with geometric mean (GM) MICs under 0.26 mg/L. The GM MIC of flucytosine was 7.33 mg/L and that of fluconazole was 4.16 mg/L. The rates of antifungal resistance were 5.3% for amphotericin B, 0.9% for voriconazole and 3.1% for ravuconazole. Fifteen point eight per cent of strains had itraconazole MICs ≥1 mg/L, and 46% of strains had flucytosine MICs ≥8 mg/L. Fluconazole susceptibility (MIC ≤8 mg/L) stood at 53.4%.

Conclusions: The percentage of fluconazole susceptibility was significantly lower than that in other surveys. Cross-resistance to itraconazole was common (33.8%) but almost the whole collection was susceptible to voriconazole and ravuconazole. These results should be confirmed with prospective and population-based surveillance programmes.

Keywords: fluconazole resistance; EUCAST; surveillance programmes

Journal Article.  2476 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.